NLS Pharmaceutics closed an initial tranche of a purchase agreement with BVF Partners as the first part of a two-tranche private placement. With the financing, NLS expects to be able to fund its operations through 2025, beyond the anticipated submission of its New Drug Application for Quilience (Mazindol ER) in narcolepsy, expected in late 2024.
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders. The company announced the closing of its purchase agreement with BVF Partners L.P. ("BVF") comprised of an initial closing of $10 million in exchange for 11,494,253 common shares (or equivalents), representing a purchase price per share of $0.87.
Up to $40 million for NLS
As part of the financing, in a second potential closing, BVF will have the right, following a successful end of phase 2 meeting with the U.S. Food and Drug Administration, among other closing conditions, to purchase units at a per unit purchase price of $1.50, which units will consist of common shares (or equivalents), as well as a common share warrant to purchase up to one and a half common shares at an exercise price of $2.03 per share. If this option is exercised in full, BVF will receive 20 million common shares plus common share warrants to purchase 20 million NLS common shares at $2.03 per share. NLS has the potential to receive $40.6 million upon the full exercise of warrants being issued in connection with the agreement.
NLS intends to use the net proceeds from the offering to accelerate the ongoing clinical development of its lead product, Mazindol ER for the treatment of narcolepsy, to advance NLS-4 and other product candidates, to support business development and licensing activities, and for general corporate purposes. With this financing, NLS expects to be able to fund its operations through 2025, beyond the anticipated submission of its New Drug Application for Mazindol ER in narcolepsy, expected in late 2024 or early 2025.
The company has received warnings from Nasdaq in recent months, among other things because the stock price was below $1. Since hitting a low of $0.35 in July, the price has recovered significantly. It is currently floating around $1. The news on financing is likely to have contributed to this.
Please login or sign up to comment.
Commenting guidelines